Jason McCarthy Reiterates Buy on MediciNova, Maintains $6 Price Target Ahead of Key ALS and Metabolic Disease Readouts
Tip Ranks·- Maxim Group analyst Jason McCarthy reaffirmed a buy rating and a 6.00 dollar target price for Medicinova. - The rating is supported by a cash reserve exceeding 25 million dollars that sustains operations until the second half of 2027 without immediate financing pressure. - Key catalysts include upcoming top-line results for MN-166 in ALS by late 2026 and Phase 2 data for MN-001 in metabolic diseases by the third quarter of 2026.